Fenwick & West represented Emulate, Inc., a leading private company that creates living products for understanding how diseases, medicines, chemicals and foods affect human health, in its $36 million Series C financing. Founders Fund led the round with participation from new investors ALS Investment Fund, SciFi VC and members of GlassWall Syndicate Association, as well as several existing investors.
With the new funding, Emulate plans to expand its suite of products within its Human Emulation System by broadening functionality and enhancing commercial efforts so that researchers in the pharmaceutical industry can use Organs-on-Chips technology across the entire drug discovery and development process. More information about Emulate’s $36 million Series C financing can be obtained from the company announcement.
The Fenwick transaction team was led by corporate lawyers Michael Esquivel, Patrick Grilli and Isabel da Roza; and technology transactions lawyer Stefano Quintini.